STOUGHTON, Mass., Sept. 14, 2020 (GLOBE NEWSWIRE) — Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a specialty pharmaceutical company committed to being the leader in responsible pain management, today announced that five poster presentations highlighting data regarding its product portfolio were presented at the 14th Annual PAINWeek National Conference which took place virtually September 11-13th.“Pursuant to Collegium’s commitment to leading with science, we were pleased to support five posters regarding our product portfolio that were presented at PAINWeek this past weekend,” said Richard Malamut, M.D., Executive Vice President and Chief Medical Officer of Collegium. “This year’s virtual scientific program provided a timely opportunity to share encouraging data around certain real-world evidence related to abuse, misuse and diversion of our product portfolio.” Poster PresentationsXtampza® ER (oxycodone) extended-release tablets, CII, Nucynta® ER (tapentadol) extended-release tablets, CII, and Nucynta® (tapentadol) tablets, CII, can be abused or misused, and carry a risk of addiction. These products are intended for use only in appropriate pain patients and only when other treatment alternatives are inadequate. Use of Xtampza® ER, Nucynta® ER and Nucynta® can result in serious, life-threatening or fatal respiratory depression, even when used exactly as prescribed. See Important Safety Information including Boxed Warning on addiction, abuse, and misuse and other serious risks regarding each of these three products at the end of this press release. For more information on PAINWeek 2020, visit https://www.painweek.org/.About Collegium Pharmaceutical, Inc.Collegium is a specialty pharmaceutical company committed to being the leader in responsible pain management. Collegium’s headquarters are located in Stoughton, Massachusetts. For more information, please visit the company’s website at www.collegiumpharma.com.About Xtampza®ERXtampza® ER is Collegium’s first product utilizing the DETERx technology platform. Xtampza ER is an abuse-deterrent, extended-release, oral formulation of oxycodone approved by the FDA for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate.INDICATIONS AND USAGE
Xtampza® ER (oxycodone) is indicated for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate.Limitations of UseBecause of the risks of addiction, abuse, and misuse with opioids, even at recommended doses, and because of the greater risks of overdose and death with extended-release opioid formulations, reserve Xtampza ER for use in patients for whom alternative treatment options (eg, non-opioid analgesics or immediate-release opioids) are ineffective, not tolerated, or would be otherwise inadequate to provide sufficient management of painXtampza ER is not indicated as an as-needed (prn) analgesicIMPORTANT SAFETY INFORMATION
Bay Street News
